Twitter | Search | |
patty spears
Cancer Research Patient Advocate
2,148
Tweets
388
Following
621
Followers
Tweets
patty spears 8h
Compelling story. ”individual perceptions of risk are influenced not only by numeric information but also personal experiences.” Yeah after having cancer ... your risk perception of another cancer may be more experiential than deliberative.
Reply Retweet Like
patty spears retweeted
Paul Kluetz 18h
If you missed the 2018 FDA Partners in Progress workshop for early career patient advocates, Webcast is now available at Kudos to FDAs Gini Kwitkowski, Aviva Krauss and Joan Todd and friends at and
Reply Retweet Like
patty spears retweeted
Dr. E Mittendorf Dec 11
QoL such an important aspect of care for the breast cancer patient. Outstanding work from Shoshana Rosenberg
Reply Retweet Like
patty spears Dec 10
Replying to @jamienholloway
I got my Christmas cards printed... not out the door yet... one step at a time...
Reply Retweet Like
patty spears Dec 10
Replying to @stage4kelly
TY. I was the substitute. Found out Monday I would be on it...
Reply Retweet Like
patty spears Dec 10
The Friday night 'View from the trenches' has an advocate. I commented on all of the overviews. Not a lot of time, but a start. Maybe make it a bigger role? It overlaps with Hot Topics
Reply Retweet Like
patty spears Dec 10
On Friday night there is an advocate on the 'view from the trenches' session. I filled in for Barbara (she had a family emergency). Most advocates are at Hot Topics at the same time. Good summary session but hate that it overlaps with the Alamo program
Reply Retweet Like
patty spears Dec 10
Liked the patient experience on accelerated partial breast irradiation vs whole breast irradiation ... cosmesis results. Trade offs for shorter duration, lower satisfaction over time ... need to know this information
Reply Retweet Like
patty spears Dec 10
The Katherine trial was presented. Patients with residual HER2+ cancer after neoadjuvant therapy did better after 1 year of T-DM1 vs Herceptin
Reply Retweet Like
patty spears Dec 10
Replying to @itsthebunk @kpasta
I was thinking the same thing. There seemed to be more on analyzing the blood (CTCs, proteins, cDNA) to try and get away from biopsies. A good thing and lots of effort in this field.
Reply Retweet Like
patty spears Dec 10
Wagle: Summary of the metastatic abstracts was great. Here's the summary
Reply Retweet Like
patty spears Dec 10
Replying to @paspears88
Winer: summary slide on 'The Challenge of Doing Less'
Reply Retweet Like
patty spears Dec 10
I liked the talks on tailoring treatment better. Addressing over and under treatment and focusing on the 'right' treatment for each patient.
Reply Retweet Like
patty spears Dec 10
Replying to @itsthebunk
Great to see you IRL too! Exhausted but rejuvenated...
Reply Retweet Like
patty spears Dec 10
Replying to @IBCResearch
I got delayed by Houston rains then NC snow, went through Chicago yesterday after spending the night with Anne
Reply Retweet Like
patty spears Dec 10
Hi all. Finally home (24 hour trip) and have my luggage (as of this afternoon) A rough trip home to NC from SABCS but so thankful to know an advocate in Houston I could stay with overnight.
Reply Retweet Like
patty spears retweeted
Daniel Stover, MD Dec 10
What a fantastic ! Thanks to the organizers and kudos to the Program Committee. Will take weeks to digest all of the fantastic work, in particular: -Remarkable talks: Lisa Coussens & debate btw 1/
Reply Retweet Like
patty spears retweeted
George W Sledge MD Dec 7
5 lessons from San Antonio: 1. PD-L1 is a good biomarker of atezolizumab benefit in TNBC. 2. Can U spell apelisib? PI3K inhibition is back. 3. T-DM1 is new SOC in post-neoadjuvant HER2+ setting. 4. Apobec3 is BAD! 5. Metastatic genomics is here to stay.
Reply Retweet Like
patty spears Dec 6
Yes. Glad to see patient perspective about cosmesis presented at the same time as primary outcome... patients need to know.
Reply Retweet Like
patty spears Dec 5
Congratulations Brinker Award winner Dr Eric Winer, for distinction in clinical research. The challenge of doing less.
Reply Retweet Like